Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective Mar 1, 2020
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives Mar 1, 2020
The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia Mar 1, 2020
Impact of the ROME II criteria – assessment of related comorbid prevalence and costs of patients with functional dyspepsia Mar 1, 2020
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective Mar 1, 2020
